The process of analyzing biological specimens (urine, hair, blood, saliva, or sweat) to detect the presence of controlled substances or their metabolites in employees or job applicants, used for pre-employment screening, random checks, post-accident analysis, and reasonable suspicion situations.
Key Takeaways
Drug testing is the process of collecting a biological sample from an employee or applicant and analyzing it in a laboratory to determine whether they've used controlled substances. For HR teams, it's one part of a broader workplace safety and compliance strategy. The practice became widespread after President Reagan's 1986 Executive Order requiring a drug-free federal workplace, followed by the Drug-Free Workplace Act of 1988 and DOT's mandatory testing regulations for safety-sensitive transportation workers. Today, nearly half of U.S. employers conduct some form of drug testing. The testing process involves three parties: the employer (who establishes the policy and authorizes tests), the collection site (where specimens are collected under controlled conditions), and the laboratory (where specimens are screened and confirmed). A Medical Review Officer (MRO), a licensed physician with specialized training, reviews all positive results before they're reported to the employer.
The reasons vary by industry and employer size. Safety is the primary driver for construction, manufacturing, transportation, and healthcare employers where impaired workers can injure or kill others. Compliance drives testing for federal contractors and DOT-regulated industries where testing is legally mandated. Cost reduction motivates many employers: workers with substance use disorders have 3.5 times higher workers' comp costs and 2.5 times more absenteeism (NSC, 2023). Some employers test primarily to reduce liability, because knowing an employee was impaired during an accident but not having tested creates significant legal exposure.
Drug testing is controversial. Proponents argue it improves safety, reduces costs, and deters substance use. Critics argue it invades privacy, disproportionately targets marijuana users (who may be using legally off-duty), and doesn't detect current impairment (a urine test for marijuana can be positive weeks after use). The debate has intensified with marijuana legalization. Many employers are reconsidering their testing policies, particularly for non-safety-sensitive positions. The question isn't whether drug testing works. It's whether the benefits justify the costs and privacy trade-offs in every context.
Different testing occasions serve different purposes and have different legal requirements. Knowing when you can test is as important as knowing how.
| Testing Occasion | When It Happens | Legal Status | Best Used For |
|---|---|---|---|
| Pre-employment | After conditional job offer, before start date | Legal in most states (restrictions in some for marijuana) | Screening candidates for safety-sensitive roles |
| Random | Selected employees tested without advance notice at random intervals | Legal in most states; DOT-mandated for safety-sensitive positions | Deterrence and ongoing compliance |
| Post-accident | After a workplace accident or near-miss meeting defined criteria | Legal in most states; DOT-mandated for covered incidents | Determining if impairment contributed to an accident |
| Reasonable suspicion | When a trained supervisor observes specific signs of impairment | Legal in all states when properly documented | Addressing observed impairment in real time |
| Return-to-duty | Before an employee returns after a substance policy violation | Required under DOT; standard practice elsewhere | Verifying fitness before resuming work |
| Follow-up | Ongoing monitoring after return-to-duty for 12 to 60 months | Required under DOT; standard practice elsewhere | Ensuring sustained recovery and compliance |
The type of specimen determines what drugs can be detected, how far back the test looks, and how easily results can be challenged.
| Specimen Type | Detection Window | Advantages | Limitations | Use Frequency |
|---|---|---|---|---|
| Urine | 1 to 30 days depending on substance and usage frequency | Most established method, accepted by DOT, extensive case law, affordable ($25-$50) | Doesn't detect current impairment, privacy concerns during collection, can be adulterated | 90%+ of workplace tests |
| Oral fluid (saliva) | 12 to 48 hours for most substances | Harder to adulterate, observed collection, detects recent use | Shorter detection window, not yet accepted for all DOT modes | Growing rapidly, 15%+ of tests |
| Hair | Up to 90 days for standard 1.5-inch sample | Longest detection window, very difficult to cheat, good for pre-employment | Expensive ($100-$150), doesn't detect very recent use, racial bias concerns (dark hair absorbs more) | 5-10% of tests |
| Blood | Hours to days depending on substance | Most accurate for current impairment, gold standard for DUI/accident investigations | Invasive, expensive, requires phlebotomist, short detection window | Rare in workplace, used for post-accident |
| Sweat (patch) | 1 to 2 weeks of continuous monitoring | Continuous detection, hard to tamper with, good for treatment monitoring | Limited lab availability, skin irritation, not widely accepted | Very rare, used in treatment programs |
The testing process follows a standardized chain of custody to ensure results are legally defensible.
The employer authorizes the test based on the applicable policy (pre-employment, random selection, post-accident criteria, or reasonable suspicion documentation). The employee is notified and directed to a collection site. For random testing, the selection must use a scientifically valid random method (not picking names from a hat). DOT requires that random selections be unannounced and that employees proceed to the collection site immediately upon notification.
At the collection site, a trained collector verifies the employee's identity, explains the process, and collects the specimen following chain-of-custody procedures. For urine tests, the employee provides a sample in a secure restroom. The collector checks the specimen's temperature (must be 90-100F within 4 minutes), appearance, and integrity. The sample is split into two bottles (primary and split specimen), sealed with tamper-evident labels, and signed by both the donor and collector. Direct observation of collection is only required in specific circumstances (return-to-duty, follow-up, or suspected tampering).
The lab runs an initial immunoassay screen on the primary specimen. This is a fast, cost-effective test that identifies specimens as negative or presumptive positive. Immunoassay screens have established cutoff levels for each substance. A specimen below the cutoff is reported as negative. A specimen at or above the cutoff proceeds to confirmatory testing. The cutoff levels are set to minimize false positives while still catching substance use.
Specimens that screen positive undergo confirmatory testing using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). These methods identify the exact substance and its concentration with 99.9% accuracy. The confirmatory cutoff is typically lower than the screening cutoff, further reducing false positives. Only specimens confirmed positive at this stage are reported to the Medical Review Officer.
The MRO is a licensed physician who reviews every confirmed positive result before it reaches the employer. They contact the donor to determine if there's a legitimate medical explanation (valid prescription, medical procedure, etc.). If the MRO verifies a legitimate explanation, the result is reported to the employer as negative. If there's no legitimate explanation, the result is reported as positive. The MRO also reviews specimens that are reported as invalid, substituted, or refused. This step is the most important protection against false positives reaching the employer.
Drug testing intersects with federal, state, and local laws. The legal framework is fragmented, and getting it wrong creates significant liability.
The Drug-Free Workplace Act of 1988 requires drug-free workplace policies for federal contractors and grantees but doesn't mandate testing. DOT regulations (49 CFR Part 40) mandate testing for safety-sensitive positions in transportation, aviation, pipeline, maritime, and transit. The DOT program is the most prescriptive: it specifies exactly which drugs to test for, what specimens to collect, what cutoff levels to use, which labs can process tests, and how results must be reported. Federal employees in specific agencies are subject to Executive Order 12564's testing requirements.
State laws range from highly permissive (employer can test almost anyone, almost any time) to highly restrictive (testing limited to safety-sensitive positions with specific procedural requirements). As of 2026, notable restrictions exist in California (no pre-employment marijuana testing for most positions starting 2024), New York City (no pre-employment marijuana testing), Nevada (can't refuse to hire based solely on a marijuana-positive pre-employment test for most positions), and Connecticut (limits random testing to specific industries). Some states require specific notice periods, written policies, or confirmatory testing before adverse action. Always verify current law in every state where you test.
The ADA prohibits employers from requiring drug tests as medical examinations before a conditional job offer. Post-offer, pre-employment testing is permitted. The ADA protects employees in recovery from substance use disorders who aren't currently using illegal drugs. Testing must be applied consistently across all employees in the same testing category. Targeting specific individuals or demographic groups for testing creates discrimination risk. Hair testing has faced legal challenges due to studies showing higher false positive rates for dark hair, which disproportionately affects Black employees.
Marijuana legalization has created the single biggest policy challenge in workplace drug testing. There's no easy answer, but there are better and worse approaches.
Urine testing for marijuana detects THC metabolites that can remain in the body for days or weeks after use, long after any psychoactive effects have worn off. An employee who legally consumed marijuana on Saturday night can test positive on Monday morning without any impairment. This gap is the core problem. Unlike alcohol, where blood alcohol concentration directly correlates with impairment, there's no validated THC threshold that reliably indicates current impairment. This means a positive marijuana test proves past use but doesn't prove the employee was impaired at work.
Oral fluid (saliva) testing has a much shorter detection window for marijuana (typically 12 to 24 hours), making it better suited for detecting recent use that's more likely to overlap with work hours. DOT added oral fluid testing as an authorized method in 2023, though implementation is still rolling out. Several states that restrict marijuana testing have carved out exceptions for oral fluid testing because it's considered a better proxy for recent use. It doesn't solve the impairment question completely, but it narrows the gap significantly.
These practices help ensure your testing program is legally defensible, operationally effective, and fair to employees.
Current data on workplace drug testing practices, positivity rates, and trends.